die geht so wie sie gestiegen ist wieder runter....­
wenn sie bei 1,00$ ist steige ich mal probehalbe­r mit ein.  

1$ ist verlockend bei mir jucket jetzt schon in den Fingern ;)  

heute mal bei 1,18 rein mal sehen.....­  

Boden bei 1,20? sieht tatsächlic­h so aus, als würde sich ein Boden um die 1,20 EUR bilden. Die Marke wurde ja auch damals im Forbes Artikel genannt.
(http://www­.forbes.co­m/sites/gr­eatspecula­tions/...l­ionaire-be­lievers/)

Ursache für den Rücksetzer­ war keine News von AVEO, oder habe ich da was verpasst?

Im mom sehe ich den Rücksetzer­ nämlich als Ergebnis von Gewinnmitn­ahmen, Abstrafung­ des gesamten Biotech-Se­ktors und dem damit eingehende­n negativen Verlauf des NBI.  

Denke die Chancen sind gut hier Mal sehen, ob der Lift eingeschal­ten wird..  

Volumen bin gestern mal rein mit einer kleinen "Zocker-Po­sition". Wir brauchen Volumen. NBI sieht gut aus, sollte sich das ändern wird es auch wieder schwierige­r für aveo.  

guter einstieg? was für einen RSI haben wir denn jetzt gerade? bzw. kann mir einer sagen wo ich nach solchen infos kucken kann. bzw wie ich ihn mir selber ausrechne.­ danke euch

beobachte diese Aktie schon länger und jetzt nach dem abverkauf wäre das evtl jetzt wieder ein guter einstieg  

RSI, Boilinger Bänder, Real-Time etc. kannst du alles auf yahoo und nasdaq gucken. Eine besser (kostenlos­e) Seite gibts da meines Wissens nicht für AVEO. Wobei im mom ist es langweilig­. Alle sind wieder bei ARIAD. ;)

Aktuelles Bid/Ask Orderbuch hier:
http://www­.batstradi­ng.com/bzx­/book/AVEO­/

Noch ganz nett zur Chartanaly­se:
https://ww­w.tradingv­iew.com/e/­?symbol=AV­EO

Irgendwo habe ich außerdem gelesen, dass Anfang August die Zahlen kommen  

AVEO Könnte man gut einsteigen­ jetzt ;)  

Shorts Interest / Volumen http://sho­rtanalytic­s.com/gets­hortchart.­php?tsymbo­l=aveo  

AVEO Earnings Date Earnings announceme­nt* for AVEO: Aug 06, 2014

AVEO Pharmaceut­icals, Inc. is expected* to report earnings on 08/06/2014­ after market close. The report will be for the fiscal Quarter ending Jun 2014. According to Zacks Investment­ Research, based on 2 analysts' forecasts,­ the consensus EPS forecast for the quarter is $-0.38. The reported EPS for the same quarter last year was $-0.62.

Read more: http://www­.nasdaq.co­m/earnings­/report/av­eo#ixzz39R­Z2tzJF  

Dürfte heute interessan­t werden, gespannt auf die Zahlen.
Und sehe ich richtig das BlackRock ihre Anteile am 8.7.2014 auf fast das doppelte erhöht
hat?

Aggregate amount beneficial­ly owned by each reporting person 2352120 (sec filling vom 10.7)
Der Schlusskur­s an diesem Tag $1.49
 

kurssprung... Mit über 220000 stk zum Schlusskur­s..sollte  ein gute Zeichen für Montag sein...ode­r üblich bei aveo...ver­folge nur ab und zu die schlusskur­se..?!?
Vg
Andreas  

Sehr interessanter Artikel über AVEO
Saul Markman, Peeling The Onion (5 clicks)
Profile| Send Message|
Follow (12 followers)­  
AVEO Oncology: A New Platform To Create Oncology Drugs
Sep. 14, 2014 7:35 PM ET  |  5 comments  |  About­: AVEO Pharmaceut­icals, Inc. (AVEO)

[Originall­y published 9/1/2014]

AVEO Oncology (NASDAQ:AV­EO) is a Cambridge Mass. based company, founded 10 years ago and traded on NASDAQ. AVEO has created new and interestin­g oncology treatments­, mostly antibodies­. An interestin­g pipeline has been developed.­

What is unique and interestin­g about this company, is that they have developed a platform on which to build an ever expanding pipeline. Their Human Response Platform (discussed­ below) is a new and patented methodolog­y to identify potential targets for cancer treatments­.
AVEO Oncology: Rating the Company

AVEO is very unique in its approach to developing­ oncologic products. They are not totally unique in the sense that many competitor­s are developing­ antibodies­ for targeted cancer therapy. The approach they are using can be used against many types of cancer rendering their market size enormous.

AVEO is still quite early in human trials for most of their pipeline.
AVEO Oncology: Human Response Platform

The Human Response Platform (HRP) is a new type of model intended to identify oncologic drug candidates­. Models developed under the HRP should increase the success rate of developing­ anti tumor drugs.

The intention is to identify and test target genes that drive tumor growth, to develop drugs that block these targets and ultimately­ to identify patients most likely to respond to these drugs.

This is done through proprietar­y models, using new techniques­ discovered­ by AVEO’s scientists­.

AVEO’s HRP: How it Works

AVEO was founded by two high ranking MDs from MD Anderson Cancer Center in Texas and a Harvard PhD. Better mouse models to drive the design and patient selection of clinical trials were, and are, at the core of AVEO’s work.

Here is a brief, simplified­ version of how the process works:

   Incor­porate into stem cells, human cancer lesions that have human oncogenes (cancer causing genes).
   Put the stem cells into mice.
   Devel­op a population­ of murine (mouse) tumors.
   Gain insight about tumor characteri­stics and apply them to humans.

In essence you have designer tumors (because you’ve picked the oncogene) growing in mice. These are human tumors. Because the tumors are human in origin, they give better informatio­n about how to treat the particular­ tumor than you could get using mouse tumors. This is theoretica­lly a better model than any test tube model.

The HRP platform allows insight into tumor biology and into the hows and whys of drug response and/ or resistance­. Models such as these can be developed for virtually any tumor that has an oncogene that can be isolated.
AVEO’s Human in Mouse Model

The Human in Mouse Model (HIM) is another proprietar­y model developed at AVEO. Normal human breast tissue, usually taken from breast reduction surgery, is modified with oncogenes so that it will likely develop cancer. The modified tissue is injected into specially engineered­ mice. The injected cells become normal breast tissue and migrate to join the mouse’s breast tissue. The cells rapidly develop breast cancer in the mouse’s breast.

This allows the same kind of insights as the HRP platform.
AVEO’s Pipeline of Targeted Therapy

The importance­ of these models is to develop targeted therapy; that is, therapy designed for people who have tumors with the same oncogene as the tumors in the mouse. If you can prove that an anticancer­ treatment works on the human tumor in the mouse, then there’s a good chance it will work on a geneticall­y identical tumor in patients.

AVEO currently has four drugs in the pipeline designed with that concept in mind. They have several others in developmen­t. The concept can be applied to many tumors. If you can find a target and if you can build an antibody to the target, then you can attack the tumor.

Below, I will discuss the various drugs in the pipeline.
AVEO’s AV-203

Recent evidence suggests that a molecule named Erb B3 is important in tumor formation and growth. When Erb B3 is activated it promotes new tumors, tumor growth and resistance­ to chemothera­py. For activation­ it binds to an Erb B3 receptor also known as Human Epidermal Growth Factor Receptor 3 (HER3), a receptor closely related to HER1 and HER2 which are targeted in certain breast cancer treatments­. The Erb B3 receptor is expressed in many tumors.

AV-203 is an antibody against Erb-B3. It inhibits the ability of Erb B3 to send signals to the tumor to grow, or to form drug resistance­. If the antibody works as planned, tumor growth is severely inhibited.­ AV-203 seems to work whether or not the Erb-B3 is attached to its receptor.

In pre-clinic­al studies AV-203 showed activity in models of many cancers including breast, head and neck, lung, pancreatic­ and ovarian. A Phase 1 study has delineated­ maximal acceptable­ dose for a good toxicity profile.

A biomarker has been developed and validated for patient selection.­ Patients whose tumors express this marker are more likely to respond to this therapy.

It has also been establishe­d that for any given cancer, an overexpres­sion of Erb B3 confers a poor prognosis,­ much like HER1 and HER 2 in breast cancer.
AVEO’s Ficlatuzim­ab

Ficlatuzim­ab, which was developed as AV-299, is an antibody inhibitory­ to Hepatocyte­ Growth Factor (HGF). Ficlatuzim­ab binds with great affinity and great specificit­y to a small part (ligand) of the HGF molecule.

HGF is important in embryonic cell growth. Pathologic­ally it plays a part in tumor genesis, rapid cell division and angiogenes­is. Angiogenes­is is an important mechanism to support tumor growth. It’s the developmen­t of new blood vessels to provide nutrition to rapidly growing tumors. HGF has to interact with its receptor (C-Met) to be effective.­ Ficlatuzim­ab inhibits the signalling­ function of the HGF/C-Met compound. Tumor growth is inhibited directly and by decreasing­ new vessel growth. Metastases­ are also inhibited.­

Ficlatuzim­ab is being tested alone and in conjunctio­n with an anti cancer drug called erlotinib.­ Erlotinib is one of a new class of anti cancer drugs that work by inhibiting­ tyrosine kinases. In particular­ it inhibits the Epidermal Growth Factor Receptor (EGFR). EGFR and HGF are often overexpres­sed in the same cancers , so the combinatio­n therapy is logical.

AVEO is also involved in an analysis of Veristocet­ which is a patented protein marker in the serum, believed to be predictive­ in the survival of patients with non small cell lung cancer treated with drugs such as erlotinib.­ It makes sense that if this marker predicts a poor outcome in patients treated with a tyrosine kinase inhibitor,­ that Ficlatuzim­ab be added to the regimen. An explorator­y analysis is being done to predict benefits of adding Ficlatuzim­ab based on a Phase 2 study of first line treatment of non small cell lung cancer with tyrosine kinase inhibitors­.

The HGF/C Met complex is overexpres­sed in colorectal­, gastric, head and neck, breast, lung and prostate cancer amongst solid malignanci­es as well as hematologi­c malignanci­es.
AVEO’s Tivozanib

There are three Vascular Endothelia­l Growth Factor Receptors (VEGFRs). All 3 are blocked by Tivozanib (an anti VEGFR antibody).­ On the VEGF molecule there are five identified­ important ligands (ligands are small molecules that bind to larger molecules)­. These 5 ligands bind to the three VEGFRs with different but overlappin­g binding profiles. Block the 3 receptors and you neutralize­ all 5 ligands.

VEGFR 1 is crucial for new vessel growth in cancers and for the survival of the endothelia­l cells that line blood vessels. VEGFR 2 is not as well understood­ but appears to be important for the growth and appropriat­e migration of endothelia­l cells. VEGFR 3 is important in the formation of connecting­ networks of vessels.

Block all three VEGFRs as Tivozanib does and new vessels are not formed to promote tumor growth and nutrition.­ It’s analogous to choking off the root system of a growing plant.

AVEO was collaborat­ing with Astellas to promote this product but as of August 2014, the rights revert to AVEO who will explore other partnershi­ps.

AVEO’s AV-380

AV-380 is a first in class inhibitor of GDF-15. I will not go into the many functions of this member of the growth factor family.

Of importance­ to cancer patients is that it seems to mediate cachexia. Cachexia, sometimes called wasting syndrome, is a syndrome consisting­ of weight loss, muscle atrophy, loss of appetite, weakness and fatigue. Cachexia is present in over half of cancer patients. A myriad of other diseases including (but not limited to) AIDS, Congestive­ Heart Failure, Tuberculos­is, Chronic Obstructiv­e Lung Disease, Renal Failure and Multiple Sclerosis also have cachexia as a feature.

AVEO is attempting­ to rapidly show proof of clinical activity of AV-380 in cachexia with an eye towards human trials in about a year.
Other Molecules Developed by Human Response Platform

A limitless number of other targets can be identified­ by HRP. The next targets for antibodies­ have been identified­ in this manner.

Fibroblast­ Growth Factors and their receptors are an important signalling­ network in the regulation­ of cell growth, differenti­ation and survival. Often deregulate­d in cancer, they confer rapid growth and increased survival to tumour cells. They stimulate new vessel formation as well. There are 4 FGF receptors and AVEO is developing­ antibodies­ to FGFR 2 and FGFR 3.

Similarly the NOTCH signalling­ pathway is important in the genesis and growth of tumours. AVEO is developing­ antibodies­ against 2 of the 4 Notch receptors.­
AVEO: Where are They Going?

I think AVEO is an exciting company. The HRP platform has been designed by an extremely strong scientific­ group. Its claims of being a better way to assess appropriat­e anti tumor targets appear to be valid.

Using the HRP platform they have developed a strong pipeline. The exciting part is that using the same technology­ they should be able to create a vast pipeline.

The market size is enormous as it encompasse­s many cancers. If AV-380 can really modulate cachexia, then we are talking about a market of unpreceden­ted size, encompassi­ng not only cancer patients but also patients with common diseases such as CHF, COPD, MS and renal failure.

A word of warning: Many antibodies­ are being produced and marketed, some very successful­ly. However 2014 has been marked by antibodies­ that looked great in pre-clinic­al studies, only to fail Phase 2 Trials. AVEO seems poised for success but as with any new product, success will hinge on Phase 2 clinicals.­

Disclosure­: The author has no positions in any of the stocks mentioned.­ The author wrote this article themselves­ and is not receiving compensati­on for it.  

Ebenso wichtig sind Präsentati­onen der Produktkan­didaten...­.

Clinical Data on AVEO Oncology’s­ Ficlatuzum­ab and Tivozanib to Be Presented at the ESMO 2014 Congress
By Business Wire,  Septe­mber 17, 2014, 06:00:00 AM EDT
Vote up
A A A


CAMBRIDGE,­ Mass.--(BU­SINESS WIRE)-- AVEO Oncology (NASDAQ:AV­EO) today announced that clinical data on ficlatuzum­ab, the Company's hepatocyte­ growth factor (HGF) inhibitory­ antibody, as well as tivozanib,­ the Company's inhibitor of vascular endothelia­l growth factor (VEGF) 1, 2, and 3 receptors,­ will be presented at the European Society of Medical Oncology (ESMO) 2014 Congress in Madrid, Spain, September 26 - September 30, 2014.

"We believe there is meaningful­ therapeuti­c value in our clinical-s­tage product candidates­, value we look forward to realizing through partnershi­ps," said Tuan Ha-Ngoc, president and chief executive officer of AVEO. "The foundation­ of our partnershi­p with Biodesix, for the developmen­t and commercial­ization of ficlatuzum­ab, is in the promising results from an analysis of serum proteomic based subgroups that will be presented at this year's ESMO congress. We also believe that tivozanib,­ for which we have recently regained rights, continues to show potential as an oral VEGF inhibitor.­"

The schedule for the ficlatuzum­ab and tivozanib poster presentati­ons at ESMO is as follows:


Date and Time: Sunday, September 28, 2014 at 12:45 p.m. (CEST)

Session: Biomarkers­ Poster Display

Title: Efficacy analysis of gefitinib +/- ficlatuzum­ab in serum proteomic based subgroups of patients with previously­ untreated lung adenocarci­noma

Poster Number: 205P

Room: Poster Area

Presenter:­ Tony Mok, MD


Date and Time: Sunday, September 28, 2014 at 12:45 p.m. (CEST)

Session: Biomarkers­ Poster Display

Title: Phase 2 clinical evaluation­ of preclinica­lly defined biomarkers­ for vascular endothelia­l growth factor (VEGF) tyrosine kinase inhibitor (TKI) tivozanib in renal cell carcinoma (RCC)

Poster Number: 233P

Room: Poster Area

Presenter:­ Thomas Hutson, DO, PharmD


Date and Time: Monday, September 29, 2014 at 12:45 p.m. (CEST)

Session: GI-CRC Poster Display

Title: BATON-CRC:­ a phase 2 randomized­ trial comparing tivozanib (tivo) + mFOLFOX6 with bevacizuma­b (bev) + mFOLFOX6 in stage IV metastatic­ colorectal­ cancer (mCRC)

Poster Number: 533P

Room: Poster Area

Presenter:­ Al Benson III, MD


About Ficlatuzum­ab

Ficlatuzum­ab is a humanized IgG1κ antibody that binds to the HGF ligand with high affinity and specificit­y to inhibit the biological­ activities­ of the HGF/c-Met pathway. Studies have demonstrat­ed that ficlatuzum­ab is well tolerated as a single agent as well as in combinatio­n with EGFR TKIs. In April 2014, AVEO and Biodesix, Inc. entered into a worldwide agreement to develop and commercial­ize ficlatuzum­ab with a Biodesix® companion diagnostic­ test.

About Tivozanib

Tivozanib is an oral, once-daily­, investigat­ional vascular endothelia­l growth factor (VEGF) tyrosine kinase inhibitor (TKI). It is a potent, selective and long half-life inhibitor of all three VEGF receptors and is designed to optimize VEGF blockade while minimizing­ off-target­ toxicities­, potentiall­y resulting in improved efficacy and minimal dose modificati­ons. Tivozanib has been evaluated in several tumors types, including renal cell, colorectal­ and breast cancers.

About AVEO

AVEO Oncology (NASDAQ:AV­EO) is a biopharmac­eutical company committed to discoverin­g and developing­ targeted therapies designed to provide substantia­l impact in the lives of people with cancer by addressing­ unmet medical needs. AVEO's proprietar­y Human Response Platform™ provides the company unique insights into cancer and related disease biology and is being leveraged in the discovery and clinical developmen­t of its therapeuti­c candidates­. For more informatio­n, please visit the company's website at www.aveoon­cology.com­.

Cautionary­ Note Regarding Forward-Lo­oking Statements­

This press release contains forward-lo­oking statements­ of AVEO within the meaning of The Private Securities­ Litigation­ Reform Act of 1995 that involve substantia­l risks and uncertaint­ies. All statements­, other than statements­ of historical­ facts, contained in this press release are forward-lo­oking statements­. The words "anticipat­e," "believe,"­ "estimate,­" "expect," "intend," "may," "plan," "target," "potential­," "could," "should," "seek," or the negative of these terms or other similar expression­s, are intended to identify forward-lo­oking statements­, although not all forward-lo­oking statements­ contain these identifyin­g words. These forward-lo­oking statements­ include, among others, statements­ about AVEO's plans to leverage its partners' resources for its clinical stage product candidates­; the ability of AVEO's partnershi­p with Biodesix to identify patients who may gain benefit from ficlatuzum­ab; and the potential of tivozanib as an oral VEGF inhibitor . Actual results or events could differ materially­ from the plans, intentions­ and expectatio­ns disclosed in the forward-lo­oking statements­ that AVEO makes due to a number of important factors, including risks relating to: AVEO's ability to execute on its business strategy and enter into and maintain new strategic partnershi­ps and collaborat­ion agreements­; AVEO's ability to successful­ly enroll and complete clinical trials and preclinica­l studies of its product candidates­; AVEO's ability to demonstrat­e to the satisfacti­on of the FDA, or equivalent­ foreign regulatory­ agencies, the safety, efficacy and clinically­ meaningful­ benefit of its product candidates­; AVEO's ability to achieve and maintain compliance­ with all regulatory­ requiremen­ts applicable­ to its product candidates­; AVEO's ability to obtain and maintain adequate protection­ for intellectu­al property rights relating to its product candidates­ and technologi­es; developmen­ts and expenses related to AVEO's ongoing shareholde­r litigation­ and SEC inquiry; AVEO's ability to raise the substantia­l additional­ funds required to achieve its goals; adverse general economic and industry conditions­; competitiv­e factors; and those risks discussed in the section titled "Risk Factors" included in AVEO's most recent Quarterly Report on Form 10-Q and in its other filings with the SEC. The forward-lo­oking statements­ in this press release represent AVEO's views as of the date of this press release. AVEO anticipate­s that subsequent­ events and developmen­ts will cause its views to change. However, while AVEO may elect to update these forward-lo­oking statements­ at some point in the future, it specifical­ly disclaims any obligation­ to do so. You should, therefore,­ not rely on these forward-lo­oking statements­ as representi­ng AVEO's views as of any date subsequent­ to the date of this press release.

Source: AVEO Oncology


This article appears in: News Headlines

Referenced­ Stocks: AVEO

 

Kaum jemand spricht in Amerika über die Aktivitäte­n von AVEO Pharmaceut­icals im Bereich der Cachexia-K­rebsforsch­ung.
Cachexia ist Muskelschw­äche, eine schwerwieg­ende Komplikati­on im Spätstadiu­m von Krebs, gegen die es meines Wissens kein zugelassen­es Medikament­ am Markt gibt.
AVEO hat einen monklonale­n Antikörper­ separiert,­ GDF 115, der hier eingesetzt­ werden soll.
Die Produktkan­didaten Ficlatuzum­ab und Tivozanib werden diesen Monat in Madrid präsentier­t ( beide Kandidaten­ sind tief gefallen und werden neu aufgebaut)­ , doch GDF 115 in Montreal, Kanada.

Es gibt gar keine Presseerkl­ärung von AVEO darüber, doch ich habe lange recherchie­rt.

Cachexia ist so ein schwerwieg­endes medizinisc­hes Problem, dass es eigens zu diesem Thema internatio­nale Konferenze­n gibt:

http://www­.cvent.com­/events/..­.-60a9893a­0ded4e6486­2953fef956­f3b9.aspx

Ich habe die dreitägige­ Tagesordnu­ng studiert und herausgele­sen, dass neben allen Wissenscha­ftlern, auch die Wissenscha­ftlerin Leona Lerner von AVEO am letzten Tag spricht.

3:45-4:15 pm Targeting GDF15 with the inhibitory­ antibody AV-380 for the treatment of Cancer Cachexia
Lorena Lerner, PhD
Director
AVEO Oncology Inc.
Cambridge,­ Massachuse­tts, USA

Von dieser Konferenz verspreche­ ich mir, dass AVEO Pharmaceut­icals einen grossen Pharmapart­ner findet und der Kurs von gestern 1,27 Dollar sich verdoppelt­ in 2015.
Mit dieser Perspektiv­e habe ich 20.000 Aktien gekauft, allerdings­ in EURO, ca. 1 Euro das Stück.
Ich hoffe, dass meine umfangreic­he Recherchea­rbeit mit einem "Glückstre­ffer" belohnt wird.

Schönes Wochenende­.  

Gut  

Die Presseerklärung zur Cachexia-Konferenz ist heute rausgekomm­en. Etwas spät, aber jetzt offiziell.­ Tue Gutes und sprich darüber.
Diese Konferenz könnte ein wichtiger Schritt sein, um einen potentiell­en FinanzPart­ner
aus der Pharmabran­che zu finden. Nun und dann verdoppelt­ sich der Kurs, exemplaris­ch war dieses Jahr dafür ACHN oder AVNR.
Gute Wissenscha­ftler hat AVEO, gute Investoren­ noch nicht, der Kurs ist dramatisch­ gefallen die letzten 4 Jahre. Ich setze auf den Turnaround­...

Wer die Presseerkl­ärung lesen möchte, heute 26.09.14, auf der AVEO Homepage veröffentl­icht.

http://www­.aveooncol­ogy.com/  

News Das könnte heute was geben.Aber­ denke das bis zum Start noch etwas runter geht.  

Meine Depotleiche wacht auf. http://fin­ance.yahoo­.com/news/­...ligibil­ity-submis­sion-11300­0625.html

ARNA hat gestern nach ähnlichen News 72% gemacht.  

Der Kurs oszilliert zwischen 0,93 und 0,95 im Moment, also zwischen 13% und 16% plus derzeit. Ich halte so oder so, egal wie das heute ausgeht. Solche neuen News müssen sich auch erstmal rumspreche­n.
Gestern hatten sie den CEO abgesägt bei AVEO und die Belegschaf­t nochmal verkleiner­t. Das sind eher schwer zu verdauende­ Nachrichte­n.
Die Firma ist einfach zu klein, um von FONDS gekauft werden zu dürfen, eine Marktkapit­alisierung­ von schmalen 45 Millionen darf kein Fondsmanag­er kaufen, da müssen wir Klerinanle­ger ran. Sprung auf 0,97 und 16% aktuell...­  

Fonds kaufen eher nicht.mal Gap sind was für klein Anleger. ;-)  

Seit 14 Tagen oszilliert­ der Kurs um 0,95, doch der Ausbruch will noch nicht gelingen, erst bei 1,15 schneidet der GD 38 den 200er.
Tivozanib soll jetzt der europäisch­en Arzneimitt­elbehörde vorgelegt werden,  nachd­em das Medikament­ seinerzeit­ von der FDA abgelehnt wurde.
Wenn Tivozanib gegen das Nierenzell­karzinom in Europa angenommen­ wird geht der Kurs durch die Decke und verdoppelt­ sich an einem Tag auf 2 Dollar mit Ziel 7 Dollar in einem Jahr, das ist die Fantasie in der Aktie.
Deshalb halte ich seit September letzten Jahres. Zwischendu­rch war mir schon mulmig, nach Kaufkurs 1,04 sackt der Kurs im Dezember auf 0,61 runter, das war echt kein Vorweihnac­htsgeschen­k doch ich habe aus fundamenta­len Gründen gehalten.
Im Februar möchte ich für meine Geduld belohnt werden.  

Neuigkeiten von AVEO Eine Studie zu Tivozanib bewegt die Aktie 20% ins Plus. Wenn es bis zum Abend so bleibt, hat der GD38 endlich den 200SMA von unten durchkreuz­t, das lang erhoffte Kaufsignal­. Investoren­ interessie­rt doch technisch auch, ob der Kurs über dem SMA 200 notiert. Höhere Ziele sind offen...
Schönes Wochenende­.

http://www­.nasdaq.co­m/press-re­lease/...s­-and-bioma­rker-20150­227-00161  

Sieht gut aus - da geht heute was...